BioCryst Pharmaceuticals
BCRX
#4741
Rank
S$2.79 B
Marketcap
S$10.95
Share price
3.14%
Change (1 day)
16.47%
Change (1 year)

BioCryst Pharmaceuticals (BCRX) - Total debt

Total debt on the balance sheet as of June 2026 : S$1.01 Billion

According to BioCryst Pharmaceuticals 's latest financial reports the company's total debt is S$1.01 Billion. A companyโ€™s total debt is the sum of all current and non-current debts.

BioCryst Pharmaceuticals - Total debt on balance sheet (from 1996 to 2026)

Total debt by year

Year Total debt Change
2025-12-31S$0.56 B-48.74%
2024-12-31S$1.09 B0.87%
2023-12-31S$1.08 B9.64%
2022-12-31S$0.99 B23.94%
2021-12-31S$0.80 B116.9%
2020-12-31S$0.36 B223.99%
2019-12-31S$0.11 B35.13%
2018-12-31S$84.45 M15.4%
2017-12-31S$73.19 M-5.87%
2016-12-31S$77.75 M82.14%
2015-12-31S$42.68 M7.69%
2014-12-31S$39.64 M4.29%
2013-12-31S$38 M3.6%
2012-12-31S$36.68 M-5.57%
2011-12-31S$38.85 M
2000-12-31S$0.01 M
1997-12-31S$0.16 M-59.84%
1996-12-31S$0.41 M

Total debt for similar companies or competitors

Company Total debt/th> differencediff. Country
Gilead Sciences
GILD
S$33.60 B 3,210.39%๐Ÿ‡บ๐Ÿ‡ธ USA
GSK plc
GSK
S$30.94 B 2,948.10%๐Ÿ‡ฌ๐Ÿ‡ง UK
Sarepta Therapeutics
SRPT
S$1.33 B 31.91%๐Ÿ‡บ๐Ÿ‡ธ USA
Repligen
RGEN
S$0.88 B-12.85%๐Ÿ‡บ๐Ÿ‡ธ USA
Novavax
NVAX
S$0.38 B-62.50%๐Ÿ‡บ๐Ÿ‡ธ USA
Celldex Therapeutics
CLDX
S$6.27 M-99.38%๐Ÿ‡บ๐Ÿ‡ธ USA
NanoViricides
NNVC
S$1.92 M-99.81%๐Ÿ‡บ๐Ÿ‡ธ USA
Cel-Sci
CVM
S$10.11 M-99.00%๐Ÿ‡บ๐Ÿ‡ธ USA
Emergent BioSolutions
EBS
S$0.74 B-26.62%๐Ÿ‡บ๐Ÿ‡ธ USA